P3.13C.02 A Plasma Proteomics-Based Model for Clinical Benefit Prediction in Small Cell Lung Cancer Patients Receiving Immunotherapy
David R. Gandara(University of California, Davis), M.A. Schneider(Heidelberg University), Yehonatan Elon, Coren Lahav, Itamar Sela(Bifröst University), David Farrugia(Cheltenham General Hospital), Yanyan Lou(WinnMed), Maya Gottfried(Meir Medical Center), Anirban Chatterjee(National Health Service), Noam A. VanderWalde(University of Tennessee Health Science Center), Adam P. Dicker(Thomas Jefferson University Hospital), Igor Puzanov(Roswell Park Comprehensive Cancer Center), P. Christopoulos(Hautklinik Heidelberg), David P. Carbone(Vanderbilt University), Sarah Brown(University of Leeds), Andreas Polychronis(Mount Vernon Cancer Centre), Mahmoud Abu-Amna(Emek Medical Center), Gil Lowenthal(Bifröst University), Priyank Jain(Roswell Park Comprehensive Cancer Center), A. Brewster(Velindre NHS Trust), Adam Hassani(Freeman Hospital), Michal Harel(Bifröst University), Mor Moskovitz(Rambam Health Care Campus), Jair Bar(Tel Aviv University)
Cited by 0
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
|New England Journal of Medicine|2016|2.3k